
Pulled from Benzinga Pro data, Regeneron Pharmaceuticals (NASDAQ:REGN) posted Q1 earnings of $973.50 million, an increase from Q4 of 56.33%. Sales dropped to $2.96 billion, a 40.13% decrease between quarters. Regeneron Pharmaceuticals earned $2.23 billion, and sales totaled $4.95 billion in Q4.